HC Wainwright Issues Positive Estimate for Rallybio Earnings

Rallybio Co. (NASDAQ:RLYB) – Research analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Rallybio in a research report issued to clients and investors on Monday, March 17th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.20) for the year, up from their prior estimate of ($1.22). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share.

Rallybio Trading Down 0.7 %

Shares of RLYB stock opened at $0.73 on Wednesday. The company has a market cap of $30.24 million, a price-to-earnings ratio of -0.46 and a beta of -1.45. The stock has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $0.97. Rallybio has a 12-month low of $0.62 and a 12-month high of $3.46.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.15 million.

Hedge Funds Weigh In On Rallybio

A number of large investors have recently modified their holdings of RLYB. Allostery Investments LP purchased a new position in shares of Rallybio during the 4th quarter worth approximately $771,000. Almitas Capital LLC increased its stake in Rallybio by 48.3% in the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after purchasing an additional 422,685 shares in the last quarter. Northeast Financial Consultants Inc increased its stake in Rallybio by 336.5% in the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock valued at $93,000 after purchasing an additional 74,334 shares in the last quarter. Renaissance Technologies LLC increased its stake in Rallybio by 9.3% in the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock valued at $424,000 after purchasing an additional 37,618 shares in the last quarter. Finally, FMR LLC increased its stake in Rallybio by 1.1% in the 3rd quarter. FMR LLC now owns 2,315,480 shares of the company’s stock valued at $2,709,000 after purchasing an additional 25,422 shares in the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.